Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Findings in cancer vaccines reported from R. Ramlau and co-researchers
August 26th, 2008
According to a study from Poznan, Poland, "TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This vector is based on the modified virus of Ankara, a significantly attenuated strain of vaccinia virus." "TG4010 has been designed to induce or amplify a cellular immune response directed against tumor cells expressing MUC1. A multicenter, randomized phase II study has explored two schedules of the combination of TG4010. with first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. In Arm 1, TG4010 was combined upfront with cisplatin (100 mg/m(2) day 1) and vinorelbine (25 mg/m(2) day 1 and day...
Source: Cancer Weekly (2008-08-26)
|
